Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 11:31 PM ET


Company Overview of Biogen Idec MA Inc.

Company Overview

Biogen Idec MA Inc. develops, manufactures, and markets novel human therapeutic products. The company focuses on developing pharmaceutical products in the areas of neurology, dermatology, and rheumatology. The company’s products include AVONEX, which is used for the treatment of relapsing multiple sclerosis; and AMEVIVE that is used for the treatment of adult patients with plaque psoriasis. Biogen Idec MA Inc. was formerly known as Biogen Inc. and changed the name to Biogen Idec MA Inc. in November 2003. The company was founded in 1978 and is based in Weston, Massachusetts. As of November 12, 2003, Biogen Idec MA Inc. operates as a subsidiary of Biogen Idec Inc.

133 Boston Post Road

Weston, MA 02493

United States

Founded in 1978

2,633 Employees



Key Executives for Biogen Idec MA Inc.

Executive Vice President of Human Resources and Executive Vice President of Public Affairs & Communications
Age: 67
Executive Officer
Age: 83
Compensation as of Fiscal Year 2015.

Biogen Idec MA Inc. Key Developments

Sangamo BioSciences, Inc. Enters into Global Research, Development and Commercialization Collaboration and License Agreement with Biogen Idec MA Inc

On January 8, 2014, Sangamo BioSciences Inc. entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen Idec MA Inc., a wholly-owned subsidiary of Biogen Idec Inc., pursuant to which Sangamo and Biogen will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo's DNA-binding technology (ZFP) for hemoglobinopathies, including beta thalassemia (BT) and sickle cell disease (SCD). Under the Agreement, Sangamo and Biogen will jointly conduct two research programs: the BT program and the SCD program. In the BT program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP therapeutic developed under the Agreement for the treatment of BT. In the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP therapeutics intended to treat SCD. Under both programs, Biogen is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any licensed product to treat BT and SCD developed under the Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. Moreover, Sangamo and Biogen agreed to form a joint steering committee, consisting of an equal number of representatives of Sangamo and Biogen, to oversee the research programs. Under the Agreement, Sangamo will receive an upfront license fee of $20.0 million. Biogen will reimburse Sangamo for its costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive development milestone payments upon the achievement of specified regulatory, clinical development and commercialization milestones. The total amount of potential regulatory, clinical development, commercialization, and sales milestone payments, assuming the achievement of all specified milestones in the Agreement and no applicable adjustments, is $293.8 million, including Phase 1 milestone payments of $7.5 million for each BT and SCD program. In addition, Biogen agrees to pay Sangamo incremental royalties for each licensed product that are tiered double-digit percentage of annual net sales of such product.

Similar Private Companies By Industry

Company Name Region
Batu Biologics, Inc. United States
Cardigant Neurovascular Inc. United States
TriLogic Pharma LLC United States
Dermatrends, Inc. United States
CyOmics, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biogen Idec MA Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at